Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use DSIP. Talk to a licensed clinician before making health decisions.
What it is
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid peptide first described in 1977. It is found in hypothalamus, limbic system, and pituitary tissue. It is proposed to modulate slow-wave sleep, pain perception, and stress hormones, but its exact receptor mechanism remains unclear.
What the evidence shows
Early animal studies suggested sleep-inducing and stress-protective effects. Human studies are small, methodologically limited, and inconsistent; some show changes in sleep architecture, others do not. There is no robust RCT evidence that DSIP treats insomnia or improves sleep quality.
Risks & unknowns
Human safety data are limited. Reported effects include headache, dizziness, and altered sleep patterns. Long-term use has not been studied, and unregulated product quality is a concern.
Legal / regulatory status
DSIP is not FDA-approved. It is not specifically listed by WADA as of 2026 but may fall under S0. It is illegal to market for human use.